help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamuta, H.
Right arrow Articles by Epand, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamuta, H.
Right arrow Articles by Epand, R. M.

Endocrinology, Vol 127, 163-169, Copyright © 1990 by Endocrine Society

ARTICLES

Evidence for calcitonin receptor heterogeneity: binding studies with nonhelical analogs

H Nakamuta, RC Orlowski and RM Epand
Department of Pharmacology, Faculty of Pharmaceutical Science, Setsunan University, Osaka, Japan.

Binding of the nonhelical salmon calcitonin (sCT) analog, [Gly8,Ala16]- des-Leu19-sCT to membrane preparations from rat brain could be analyzed in terms of two independent binding sites. The high and low affinity binding sites for this analog were named CT-L (L, linear) and CT-H (H, helix), respectively. Although the CT-H type receptor has a low affinity for the nonhelical analogs, it binds the helical sCT with high affinity and therefore represents a CT binding site. The physiological significance for the existence of subtypes of specific CT receptors is not clear. The [Gly8,Ala16]-des-Leu19-sCT suppressed the osteoclastic bone resorption in tissue culture at low concentration (0.1 nM). The dose of [Gly8,Ala16]-des-Leu19-sCT required for this hypocalcemic activity was highly correlated with the binding affinity of this analog to the CT-L receptor subtype. In addition, human CT interacted with the CT-L type receptor at about 100th the concentration of that required for the displacement of sCT. We conclude that binding to the CT-L type receptor is required for hypocalcemic activity in mammals.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
G. Andreotti, B. L. Mendez, P. Amodeo, M. A. C. Morelli, H. Nakamuta, and A. Motta
Structural Determinants of Salmon Calcitonin Bioactivity: THE ROLE OF THE LEU-BASED AMPHIPATHIC {alpha}-HELIX
J. Biol. Chem., August 25, 2006; 281(34): 24193 - 24203.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
K. Wagner, N. Van Mau, S. Boichot, A. V. Kajava, U. Krauss, C. Le Grimellec, A. Beck-Sickinger, and F. Heitz
Interactions of the Human Calcitonin Fragment 9-32 with Phospholipids: A Monolayer Study
Biophys. J., July 1, 2004; 87(1): 386 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
D. R. Poyner, P. M. Sexton, I. Marshall, D. M. Smith, R. Quirion, W. Born, R. Muff, J. A. Fischer, and S. M. Foord
International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors
Pharmacol. Rev., June 1, 2002; 54(2): 233 - 246.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society